Celyad Appoints Carri Duncan as Vice-President Corporate Development & Communications
September 26, 2018 01:00 ET
|
Celyad SA
MONT-SAINT-GUIBERT, Belgium, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T...
Celyad to Participate at Upcoming Healthcare Conferences
September 25, 2018 01:00 ET
|
Celyad SA
MONT-SAINT-GUIBERT, Belgium, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T...
Celyad Successfully Doses First Colorectal Cancer Patient With CYAD-01 Following Preconditioning Chemotherapy
September 05, 2018 01:00 ET
|
Celyad SA
No toxicity observed to date in first patient enrolled in the amended THINK trial evaluating the safety and anti-tumor response of CYAD-01 after preconditioning chemotherapy in colorectal cancer...
Celyad to Participate at Upcoming Healthcare Conferences in September
August 30, 2018 01:00 ET
|
Celyad SA
MONT-SAINT-GUIBERT, Belgium, Aug. 30, 2018 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T...
Celyad Reports First Half 2018 Financial Results and Operational Progress
August 23, 2018 01:00 ET
|
Celyad SA
Conference call scheduled for Thursday, 23 August at 2:00 p.m. CEST / 8:00 a.m. EDT Dose escalation portion of THINK1 clinical trial in solid arm completed Successful administration of CYAD-01 in...
Celyad Appoints Filippo Petti as Chief Financial Officer
August 07, 2018 01:00 ET
|
Celyad SA
MONT-SAINT-GUIBERT, Belgium, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T...
Dr. Margo Roberts Joins Celyad’s Board of Directors and Scientific Committee
August 01, 2018 01:00 ET
|
Celyad SA
MONT-SAINT-GUIBERT, Belgium , Aug. 01, 2018 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T...
Celyad Announces FDA Acceptance of IND Application for CYAD-101, a First-in-Class Non-Gene Edited Allogeneic CAR-T Candidate
July 24, 2018 01:00 ET
|
Celyad SA
FDA acceptance of IND for world’s first non-gene edited allogeneic CAR-T clinical programFirst of a family of non-gene edited allogeneic CAR-T, targeting colorectal cancer to build on the experience...
Celyad Doses First AML Patient at Final Dose Level in CYAD-01 THINK Trial and Begins Dosing First Patient With Second Cycle of Therapy
June 19, 2018 01:00 ET
|
Celyad SA
Celyad advances THINK trial to third and final dose level in hematological study armSecond cycle treatment amendment in THINK protocol approved and first patient dosed MONT-SAINT-GUIBERT, Belgium,...
Celyad Announces Closing of Global Offering
May 23, 2018 01:00 ET
|
Celyad SA
MONT-SAINT-GUIBERT, Belgium, May 23, 2018 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels:CYAD) (Euronext Paris:CYAD) (NASDAQ:CYAD), a clinical-stage biopharmaceutical company focused on the...